442 related articles for article (PubMed ID: 30589955)
1. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
[TBL] [Abstract][Full Text] [Related]
2. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
4. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.
Sardi SP; Cheng SH; Shihabuddin LS
Prog Neurobiol; 2015 Feb; 125():47-62. PubMed ID: 25573151
[TBL] [Abstract][Full Text] [Related]
5.
Granek Z; Barczuk J; Siwecka N; Rozpędek-Kamińska W; Kucharska E; Majsterek I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768367
[TBL] [Abstract][Full Text] [Related]
6. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
7. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
8. Measurement of GCase Activity in Cultured Cells.
Shojima Y; Ogata J; Tsunemi T; Imai Y; Hattori N
Methods Mol Biol; 2021; 2322():47-52. PubMed ID: 34043191
[TBL] [Abstract][Full Text] [Related]
9. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
[TBL] [Abstract][Full Text] [Related]
10. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
12. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson's Disease Research.
Jong T; Gehrlein A; Sidransky E; Jagasia R; Chen Y
J Parkinsons Dis; 2024; 14(1):65-78. PubMed ID: 38251062
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
15. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
16. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
[TBL] [Abstract][Full Text] [Related]
17. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
Stojkovska I; Krainc D; Mazzulli JR
Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
[TBL] [Abstract][Full Text] [Related]
20. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
